International guidelines for the treatment of peritoneal cancer: clinical pathways of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy
10.3969/j.issn.1000-8179.2020.11.636
- Author:
Paul H. SUGARBAKER
1
Author Information
1. Center for Gastrointestinal Malignancies, MedStar Washington Hospital Center
- Publication Type:Journal Article
- Keywords:
Clinical pathway;
Cytoreductive surgery (CRS);
Intraperitoneal hyperthermic chemotherapy (HIPEC);
Peritoneal cancer
- From:
Chinese Journal of Clinical Oncology
2020;47(11):541-551
- CountryChina
- Language:Chinese
-
Abstract:
Peritoneal cancer originates from a wide range of tumor sources and is associated with poor prognosis. Standardized therapy is of great significance in the treatment for patients with peritoneal cancer. The Peritoneal Surface Oncology Group International (PSOGI) instituted guidelines for peritoneal metastases. This article uses the Chinese version, which is divided into four parts: preoperative evaluation, surgery, chemotherapy, and clinical pathway. The preoperative evaluation consists of preoperative computed tomography, prognostic evaluation model, diagnostic laparoscopic exploration, the peritoneal cancer index, and the cytoreduction score. Peritoneal cancer treatment primarily consists of comprehensive treatment with cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy. However, complete CRS is the key to the long-term survival of patients. Peritoneal cancer chemotherapy generally includes perioperative chemotherapy and regional chemotherapy. Finally, this guide outlines the clinical pathways. The Chinese version of the guidelines was published under the permission of the Secretary-General of the PSOGI Executive Committee.
